Hemalata Hospitals and Research Centre, Bhubaneswar has been successfully rendering dedicated service to cancer patients since its inauguration on 27 December 2005.by the then Honorable President of India, Dr. APJ Abdul Kalam. Hemalata Hospitals and Research Center is a superspecialty Hospital for treatment of Cancer and houses many sophisticated medical devices including the only Linear Accelerator between Chennai and Kolkata and the first integrated CT Simulator of the country.Read more...

Latest News

Required  Consultant in Surgical Oncology / Consultant in Medical Oncology,for more details visit our Career Page.

 

Hemalata Hospital Bhubaneswar is a cancer superspeciality hospital with state of the art facility for comprehensive cancer care which is running smoothly for surgery/chemotherapy/radiotherapy.We are open at your service. For appointment please call (0674) 2302333/2302444 or visit our website : www.hemalatahospitals.com

 

 

On the Occasion of Doctor's Day -1st July 2017, Dr.Prakash Kumar Swain, MD, DNB, Consultant, Clinical & Radiation Oncology, Hemalata Hospitals & Research Centre, Bhubaneswar, delivered Cancer Awareness talk at NTPC, Kaniha, Talcher.

 

 


Hemalata Hospitals & Research Centre observed World No Tobacco Day 2016 in association with IMA, Bhubaneswar Branch and Govt. of Odisha.


Awareness Rally On World No Tobacco Day, 31st May, 2015 Organized by- State Tobacco Control Cell, Directorate of Public Health, H & FW Department, Govt. of Odisha in Collaboratoin with Hemalata Hospitals & Research Centre, Bhubaneswar and Indian Medical Association-Bhubaneswar.


 Our Chairman Dr. Arabinda Kumar Rath moderating a live session on Social Innovations on  NDTV


 

Profile Summary:

A Competent Professional with more than 6 years of experience in the field of Radiation Oncology with the   experience of  working at PGIMER, Chandigarh & AIIMS, Bhubaneswar.

Experienced in working with Radiotherapy machines like C060, LINACs (TRIOLOGY, Versa HD), Gamma knife, Microselectron HDR  brachy therapy.

Experienced in administering EBRT with the different techniques like 3DCRT,IMRT,VMAT,IGRT,SRS,SRT,Electron beam therapy.

Experienced in delivering Intracavitary, Interstitial & Intraluminal brachytherapy.

Experienced in Prescribing Chemotherapy regimens as appropriate to assessed Cancer type & staging.

Qualification :

MD,Radiation Oncology from PGIMER,Chandigarh.

DNB,Radiation Oncology from NBE,Delhi.

MBBS, from SCB Medical College, Cuttack.

Other Courses :

ICRO teaching course (Management of Brain Tumors) at R.R Cancer Institute, Bareilly,UP

A Course on Clinical Radiobiology for Radiation Oncologist at IGMC, Shimla.

ICRO teaching Course (Oncology Imaging & Geriatric Oncology) at KGMU, Lucknow.

A Course on Research Methodology & Biostatistics from PGIMER, Chandigarh.

CME on Advanced Radiotherapy Techinques-Treatment Planing & Delivery (IMRT,IGRT,VMAT,SBRT) at PGIMER Chandigarh.

Passed FRCR (Clinical Oncology) Part 1.

Participated in 1st International Proton Therapy Education Programme at Chennai.

Certificate Course of Palliative Care by IAPC.

Attended a Workshop on Brachythevapy of GI Cancers at PGIMER, Chandigarh.

Clinical Paper & Presentations:

Publised a case report :- A Rare case of Primitive Neuro ectodermal Tumor of the kindney with Review of Literature, Journal  of Tumor 2015;4(3):445-447.

Presented Paper :- Assessment of Radiation Dose to the Left Anterior Descending Coronary Artery in Patient with Lift breast Cancer at AROICON 2015.

Presented Paper :- Male breast Cancer - Clinical Presentation, diagnosis & treatment : 5 year clinical experience from a tertiary cancer unit at 3rd OSO-8th AROI Odisha chapter 2018.

Presented on Topic :- EBCTCG Meta analysis- Radiotherapy at DOTS Programme 2019,AIIMS,BBSR.

Thesis :

Assessment of the Radiation Dose to the Left anterior descending Coronary artery (LAD) in patients with left breast cancer.

Project :

  1. As a Co-investigator in prospective single arm post marketing phase IV study to assess the safety & efficacy of Lenvatinib in subjects with locally advanced or metastatic, progressive, radioiodine refractory differentiated thyroid cancer.
  2. As a Co-investigator in the efficacy & safety study of INTAS Denosumab in Comparision with Xgeva in patients with solid tumors with bone metastasis.

 Professional Membership:

AROI, ESMO, ASCO, ASTRO, ESTRO, National Academy of Medical Science (NAMS).

Case-Study Success Studies

Our Milestones